Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
Holding INZY?
Track your performance easily
INZY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.69 - $7.80
Previous Close$5.81
Volume182.82K
Average Volume (3M)304.10K
Market Cap
$364.49M
Enterprise Value$266.67M
Total Cash (Recent Filing)$144.52M
Total Debt (Recent Filing)$46.71M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Nov 05, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding67,100,000
10 Day Avg. Volume217,480
30 Day Avg. Volume304,098
Standard Deviation0.31
R-Squared0.06
Alpha-0.00952
Financial Highlights & Ratios
Price to Book (P/B)4.12
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$17.00Price Target Upside194.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Inozyme Pharma News
PremiumStock Analysis & Ideas
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessINZ-701 displayed a favorable safety profile with no serious or severe adverse events.
Market OpportunityAnalyst believes investors underappreciate the commercial opportunity in ENPP1.
Regulatory MilestonesThe FDA has granted Fast Track Designation for INZ-701 for the treatment of ABCC6 Deficiency.
Bears Say
Clinical TrialsThe core of a potential FDA filing in ENPP1 deficiency is expected to come from the randomized ENERGY-3 trial in pediatric ENPP1 patients aged 1-13.
Mixed Program UpdatesINZY shares reacted negatively post the recent mixed update on ABCC6, and there are some questions regarding the program including endpoint selection and regulatory buy-in.
Regulatory ChallengesINZY faces well-known challenges in rare disease drug development, including real world patient identification and disease awareness, few/no regulatory comparisons, and limited data on certain indications.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INZY FAQ
What was Inozyme Pharma’s price range in the past 12 months?
Inozyme Pharma lowest stock price was $2.69 and its highest was $7.79 in the past 12 months.
What is Inozyme Pharma’s market cap?
Currently, no data Available
When is Inozyme Pharma’s upcoming earnings report date?
Inozyme Pharma’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Inozyme Pharma’s earnings last quarter?
Inozyme Pharma released its earnings results on Aug 06, 2024. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.397 by -$0.043.
Is Inozyme Pharma overvalued?
According to Wall Street analysts Inozyme Pharma’s price is currently Undervalued.
Does Inozyme Pharma pay dividends?
Inozyme Pharma does not currently pay dividends.
What is Inozyme Pharma’s EPS estimate?
Inozyme Pharma’s EPS estimate is -$0.44.
How many shares outstanding does Inozyme Pharma have?
Inozyme Pharma has 62,734,394 shares outstanding.
What happened to Inozyme Pharma’s price movement after its last earnings report?
Inozyme Pharma reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.397. Following the earnings report the stock price went up 0.213%.
Which hedge fund is a major shareholder of Inozyme Pharma?
Among the largest hedge funds holding Inozyme Pharma’s share is Woodline Partners LP. It holds Inozyme Pharma’s shares valued at 4M.
---
Inozyme Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (194.12% Upside)
$17.00 (194.12% Upside)
Blogger Sentiment
Bullish
INZY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 122.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 19.8%
Last 30 Days ▲ 19.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.05%
12-Months-Change
Fundamentals
Return on Equity
-88.56%
Trailing 12-Months
Asset Growth
3.17%
Trailing 12-Months
Company Description
Inozyme Pharma
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
---
INZY Stock 12 Month Forecast
Average Price Target
$17.00
▲(194.12% Upside)
Technical Analysis
Best Analysts Covering INZY
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+29.18%
reiterated a buy rating 2 months ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +29.18% per trade.
---